Home News

First quarter 2019 results presentation

Operating income, growth figures, profitability and how our products have behaved

Wed, 08/05/2019 - 12:15 0 min
Download related document
No votes yet
 
Related
ROVI announces an agreement with Biogaran for the marketing of its enoxaparin...
0 min
20/09/2018
ROVI has commenced the marketing of its enoxaparin biosimilar in Spain
0 min
19/09/2018
Press release - Grant for research project
Awarded a partially refundable grant for research project: Bluespe
1 min
31/07/2018